Progression to rheumatoid arthritis in early inflammatory arthritis is associated with low IL-7 serum levels

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 1032-1036

  Goëb, Vincent ^{a,b,c,d,e,f,g}   Aegerter, Philippe ^{a,b,c,d,e,f,g}   Parmar, Rekha ^{a,b,c,d,e,f,g}   Fardellone, Patrice ^{a,b,c,d,e,f,g}   Vittecoq, Oliver ^{a,b,c,d,e,f,g}   Conaghan, Philip G ^{a,b,c,d,e,f,g}   Emery, Paul ^{a,b,c,d,e,f,g}   Loët, Xavier Le ^{a,b,c,d,e,f,g}   Ponchel, Frédérique ^{a,b,c,d,e,f,g}  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE ROUEN   (France)

^g CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; INTERLEUKIN 7;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS;

CYTOKINES; EARLY RHEUMATOID ARTHRITIS; QUALITATIVE RESEARCH;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-7; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84877609749     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202377     Document Type: Article

References (45)

1. Emery P, Kvien T, Combe B, et al. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Ann Rheum Dis 2012;71:989-92.
2. Goëb V, Jouen F, Gilbert D, et al. Diagnostic and prognostic usefulness of antibodies to citrullinated peptides. Joint Bone Spine 2009;76:343-9.
3. Jansen A, van der Horst-Bruinsma I, van Schaardenburg D, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatology 2002;29:2074-6.
4. Kallberg H, Padyukov L, Plenge R, et al. Epidemiological Investigation of Rheumatoid Arthritis study group. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80:867-75. (Pubitemid 46668455)
5. Goëb V, Dieudé P, Vittecoq O, et al. Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis. Arthritis Res Ther 2005;7:1056-62.
6. Goëb V, Dieudé P, Daveau R, et al. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis. Rheumatol 2008;47:1208-12.
7. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 2001;22:564-71. (Pubitemid 33016404)
8. Ponchel F, Verburg R, Bingham S, et al. IL-7 deficiency and therapy-induced lymphopenia in rheumatoid arthritis. Arthritis Res Ther 2005;7:80-92.
9. Ponchel F, Cuthbert RJ, Goëb V. IL-7 and lymphopenia. Clin Chim Acta 2011;412:7-16.
10. Foxwell B, Beadling C, Guschin D, et al. Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine T-cells. Eur J Immunol 1995;25:3041-6.
11. Page T, Lali F, Foxwell B. Interleukin-7 activates p56lck and p59fyn, two tyrosine kinases associated with the p90 interleukin-7 receptor in primary human T-cells. Eur J Immunol 1995;25:2956-60.
12. Crawley J, Rawlinson L, Lali F, et al. T-cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem 1997;272:15023-7. (Pubitemid 27251779)
13. Churchman S, Ponchel F. IL-7 in rheumatoid arthritis. Rheumatology 2008;6:753-9.
14. Emery P, Panayi GS, Nouri AME. Interleukin-2 reverses deficient cell-mediated immune-responses in rheumatoid-arthritis. Clin Exp Immunol 1984;57:123-9. (Pubitemid 14083836)
15. Harada S, Yamamura M, Okamoto H, et al. Production of interleukin-7 and interleukin-15 by fibroblast- like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999;42:1508-16.
16. van Roon J, Verweij M, Wenting-van Wijk M, et al. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4+ T-cells and macrophages. Arthritis Rheum 2005;52:1700-10.
17. Natsumeda M, Nishiya K, Ota Z. Stimulation by interleukin-7 of mononuclear-cells in peripheral-blood, synovial-fluid and synovial tissue from patients with rheumatoid-arthritis. Acta Medica Okayama 1993;47:391-7.
18. Makino T, Fukushima S, Wakasugi S, et al. Decreased serum IL-7 levels in patients with systemic sclerosis. Clin Exp Rheumatol 2009;27:68-9.
19. Kader HA, Tchernev VT, Satyaraj E, et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta 1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 2005;100:414-23. (Pubitemid 40314529)
20. Lanfant-Weybel K, Michot CDR, Milliez P, et al. Synovium CD20 expression is a potential new predictor of bone erosion progression in very-early arthritis treated by sequential DMARDs monotherapy - a pilot study from the VErA cohort. Joint Bone Spine Published Online First: 27 Mar 2012. doi: 10.1016/j.jbspin. 2011.11.006.
21. Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011;108:17372-7.
22. Nissim A, Winyard PG, Corrigall V, et al. Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Arthritis Rheum 2005;52:3829-38. (Pubitemid 41798221)
23. Hughes C, Faurholm B, Dell'Accio F, et al. Targeting therapeutics to arthritis joints by antibody specific to post translationally modified collagen type II. Ann Rheum Dis 2012;71:A7. doi:10.1136/annrheumdis-2011-201230.16.
24. Hueber W, Tomooka B, Zhao X, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007;66:712-19. (Pubitemid 46846688)
25. Klein-Wieringa I, van der Linden M, Kneve lR, et al. Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011;63:2567-74.
26. Romero-Sanchez C, Robinson W, Tomooka B, et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 2008;27:1429-35.
27. Goekoop-Ruiterman Y, De Vries-Bouwstra J, Ronday H, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010;69:1333-7.
28. Kaltenhäuser S, Pierer M, Arnold S, et al . Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis. Rheumatology 2007;46:100-4. (Pubitemid 44932795)
29. Le Loët X, Brazier M, Mejjad O, et al. Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort. Arthritis Care Res 2010;62:1739-47.
30. Klein-Wieringa I, van der Linden M, Knevel RK, et al. Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis Rheum 2011;63:2567-74.
31. Lee SK, Surh CD. Role of interleukin-7 in bone and T-cell homeostasis. Immunol Rev 2005;208:169-80. (Pubitemid 41746392)
32. Lee S, Kalinowski JF, Cabrera-Hernandez A, et al. Interleukin-7 influences osteoclast and osteoblast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res 2003;18:S327.
33. Weitzmann MN, Roggia C, Toraldo G, et al. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002;110:1643-50. (Pubitemid 35424242)
34. Miyaura C, Onoe Y, Inada M, et al. Increased B-lymphopoiesis by IL-7 treatment induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. J Bone Miner Res 1997;12:93-4.
35. Burgoyne C, Field S, Brown AK, et al. Abnormal T-cell differentiation persists in rheumatoid arthritis patients in clinical remission and predicts relapse. Ann Rheum Dis 2008;67:7507.
36. Jayakumar K, Norton S, Dixey J, et al. Early Rheumatoid Arthritis Study (ERAS). Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology 2012;51:169-75.
37. Aspinall R. T-cell development, ageing and interleukin-7. Mech Ageing Dev 2006;127:572-8.
38. Faucher S, Crawley A, Decker W, et al. Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma. PLoS One 2009;4:e6690.
39. Crawley AM, Faucher S, Angel JB. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol 2010;184:4679-87.
40. Witkowska AM. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005;14:121-30. (Pubitemid 41381519)
41. Klimiuk PA, Sierakowski S, Latosiewicz R, et al. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin Exp Rheumatol 2003;21:63-9. (Pubitemid 36267533)
42. Houssiau F, Lauwerys B, Badot V, et al. sIL-7R is a novel marker of disease activity in systemic lupus erythematosus nephritis, which reflects target organ involvement. (abstract). Arthritis Rheum 2012;30:534-42.
43. Badot V, Durez P, Van den Eynde BJ, et al. Rheumatoid arthritis synovial fibroblasts produce a soluble form of the interleukin-7 receptor in response to pro-inflammatory cytokines. J Cell Mol Med 2011;15:2335-42.
44. Churchman S, Geiler J, Parmar R, et al. Multiplexing immunoassays for cytokine detection in the serum of patients with rheumatoid arthritis: lack of sensitivity and interference by rheumatoid factor. Clin Exp Rheumatol 2012;30:Oral Presentation Number 2258.
45. Stabler T, Piette JC, Chevalier X, et al. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum 2004;50:3663-7. (Pubitemid 39488695)